| Literature DB >> 32709254 |
Hongzhi Liu1,2, Yuan Yang3, Chuanchun Chen4, Lei Wang1, Qizhen Huang1, Jianxing Zeng1,2, Kongying Lin1,2, Yongyi Zeng1,2, Pengfei Guo1, Weiping Zhou5, Jingfeng Liu6,7.
Abstract
BACKGROUND AND OBJECTIVES: Tumor size is one of the most important issues for hepatocellular carcinoma (HCC) treatment and prognosis, but the classification of it is still controversial. The aim of this study was to screen appropriate cutoffs for size of solitary hepatitis B virus (HBV)-related HCC.Entities:
Keywords: Hepatocellular carcinoma; Prognosis; Solitary; Tumor size
Mesh:
Year: 2020 PMID: 32709254 PMCID: PMC7382134 DOI: 10.1186/s12957-020-01963-z
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
The clinicopathologic factors of solitary HBV-related HCC patients who underwent initial hepatectomy (n = 1760)
| Parameter | Value |
|---|---|
| Age, years | 50.7 ± 10.2 |
| Sex | |
| Male | 1497 (85.1%) |
| Female | 263 (14.9%) |
| α-Fetoprotein, ng/mL | |
| ≤ 20 | 726 (41.2%) |
| 20–400 | 451 (25.6%) |
| ≥ 400 | 583 (33.1%) |
| HBV DNA, IU/ml | |
| ≤ 1000 | 801 (45.5%) |
| > 1000 | 959 (54.5%) |
| White blood cells, 109/L | 5.26 ± 1.74 |
| Platelet count, 109/L | 152 (23-479) |
| Albumin, g/L | 41.7 ± 3.74 |
| Total bilirubin, μmol/L | 13.4 (3.3–45.4) |
| γ-Glutamyl transferase, IU/L | 55.0 (10–1175) |
| Alkaline phosphatase, IU/L | 80.0 (17–1155) |
| ALBI grade | |
| ≤ − 2.63 | 1270 (72.2%) |
| > 2.63 | 490 (27.8%) |
| Blood loss, mL | |
| < 800 | 1650 (93.8%) |
| ≥ 800 | 110 (6.2%) |
| Tumor size, cm | 5.55 ± 3.48 |
| Differentiation degree | |
| I/II | 295 (16.8%) |
| III/IV | 1465 (83.2%) |
| Microvascular invasion | |
| Absent | 1354 (76.9%) |
| Present | 406 (23.1%) |
| AJCC stage | |
| T1a | 121 (6.9%) |
| T1b | 1250 (71.0%) |
| T2 | 389 (22.1%) |
| BCLC stage | |
| 0 | 121 (6.9%) |
| A | 1639 (93.1%) |
| Tumor capsule | |
| Incomplete/absent | 1232 (70.0%) |
| Complete | 528 (30.0%) |
| Cirrhosis | |
| Absent | 927 (52.7%) |
| Present | 833 (47.3%) |
Values shown are mean ± SD, median (range), or n (%)
Fig. 1Overall survival of patients with solitary HBV-related HCC following liver resection, classified by tumor size into 11 groups differing at 1.0-cm intervals
The p values of log-rank test and HR values for OS of each dichotomy size cutoff
| Cutoffs | Log-rank OS | Cox |
|---|---|---|
| HR-OS (95% CI) | ||
| 1 cm | 0.40435 | |
| 2 cm | 0.00016 | |
| 3 cm* | < 0.0001 | 1.702 (1.408–2.059) |
| 4 cm* | < 0.0001 | 1.881 (1.613–2.194) |
| 5 cm* | < 0.0001 | 1.87 (1.615–2.164) |
| 6 cm* | < 0.0001 | 2.049 (1.766–2.377) |
| 7 cm* | < 0.0001 | 1.968 (1.683–2.302) |
| 8 cm* | < 0.0001 | 1.948 (1.650–2.299) |
| 9 cm* | < 0.0001 | 2.074# (1.737–2.476) |
| 10 cm* | < 0.0001 | 2.013 (1.662–2.439) |
OS overall survival, HR hazard ratio, CI confidence interval
*The p values of log-rank test for OS of size cutoff had significant statistical difference (p < 0.0001); # The highest HR value of Cox proportional analysis for OS
The p values of log-rank test and HR values for OS of each trichotomy size cutoff
| Cutoffs (cm) | HR (95% CI) of Cox | |||||
|---|---|---|---|---|---|---|
| A | B | ≤ A vs. A~B | ≤ A vs. > B | A~B vs. > B | A~B vs. ≤ A | > B vs. ≤ A |
| 1 | 2 | 0.611280 | 0.417322 | 0.000224 | ||
| 1 | 3 | 0.401394 | 0.424487 | < 0.0001 | ||
| 1 | 4 | 0.588828 | 0.327959 | < 0.0001 | ||
| 1 | 5 | 0.566227 | 0.277350 | < 0.0001 | ||
| 1 | 6 | 0.545619 | 0.222792 | < 0.0001 | ||
| 1 | 7 | 0.493309 | 0.263552 | < 0.0001 | ||
| 1 | 8 | 0.482870 | 0.257788 | < 0.0001 | ||
| 1 | 9 | 0.460243 | 0.289755 | < 0.0001 | ||
| 1 | 10 | 0.444595 | 0.325466 | < 0.0001 | ||
| 2 | 3 | 0.083743 | < 0.0001 | < 0.0001 | ||
| 2 | 4 | 0.103040 | < 0.0001 | < 0.0001 | ||
| 2 | 5 | 0.029683 | < 0.0001 | < 0.0001 | ||
| 2 | 6 | 0.018186 | < 0.0001 | < 0.0001 | ||
| 2 | 7 | 0.005548 | < 0.0001 | < 0.0001 | ||
| 2 | 8 | 0.002914 | < 0.0001 | < 0.0001 | ||
| 2 | 9 | 0.001960 | < 0.0001 | < 0.0001 | ||
| 2 | 10 | 0.001138 | < 0.0001 | < 0.0001 | ||
| 3 | 4 | 0.451643 | < 0.0001 | < 0.0001 | ||
| 3 | 5 | 0.028445 | < 0.0001 | < 0.0001 | ||
| 3 | 6 | 0.009799 | < 0.0001 | < 0.0001 | ||
| 3 | 7 | 0.000557 | < 0.0001 | < 0.0001 | ||
| 3 | 8* | < 0.0001 | < 0.0001 | < 0.0001 | 1.472 (1.208–1.793) | 2.574 (2.058–3.219) |
| 3 | 9* | < 0.0001 | < 0.0001 | < 0.0001 | 1.497 (1.23–1.82) | 2.79# (2.21–3.523) |
| 3 | 10* | < 0.0001 | < 0.0001 | < 0.0001 | 1.542 (1.27–1.874) | 2.781 (2.176–3.554) |
| 4 | 5 | 0.000843 | < 0.0001 | 0.001334 | ||
| 4 | 6 | 0.000214 | < 0.0001 | < 0.0001 | ||
| 4 | 7* | < 0.0001 | < 0.0001 | < 0.0001 | 1.566 (1.312–1.868) | 2.405 (2.009–2.879) |
| 4 | 8* | < 0.0001 | < 0.0001 | < 0.0001 | 1.63 (1.376–1.932) | 2.464 (2.038–2.978) |
| 4 | 9* | < 0.0001 | < 0.0001 | < 0.0001 | 1.646 (1.395–1.944) | 2.67 (2.184–3.263) |
| 4 | 10* | < 0.0001 | < 0.0001 | < 0.0001 | 1.702 (1.447–2.004) | 2.662 (2.148–3.299) |
| 5 | 6 | 0.074289 | < 0.0001 | < 0.0001 | ||
| 5 | 7 | < 0.0001 | < 0.0001 | 0.000524 | ||
| 5 | 8 | < 0.0001 | < 0.0001 | 0.001047 | ||
| 5 | 9* | < 0.0001 | < 0.0001 | < 0.0001 | 1.602 (1.352–1.9) | 2.42 (2.004–2.922) |
| 5 | 10 | < 0.0001 | < 0.0001 | 0.000794 | ||
| 6 | 7 | < 0.0001 | < 0.0001 | 0.381256 | ||
| 6 | 8 | < 0.0001 | < 0.0001 | 0.255359 | ||
| 6 | 9 | < 0.0001 | < 0.0001 | 0.025411 | ||
| 6 | 10 | < 0.0001 | < 0.0001 | 0.069108 | ||
| 7 | 8 | 0.000275 | < 0.0001 | 0.449406 | ||
| 7 | 9 | < 0.0001 | < 0.0001 | 0.037663 | ||
| 7 | 10 | < 0.0001 | < 0.0001 | 0.109361 | ||
| 8 | 9 | 0.044308 | < 0.0001 | 0.042670 | ||
| 8 | 10 | < 0.0001 | < 0.0001 | 0.166143 | ||
| 9 | 10 | < 0.0001 | < 0.0001 | 0.944208 | ||
OS overall survival, HR hazard ratio, CI confidence interval
*The p values of log-rank test for OS of size cutoff had significant statistical difference (p < 0.0001); # The highest HR value of Cox proportional analysis for OS
Comparison of clinicopathologic characteristics among three new classifications
| Parameter | ≤ 3 cm ( | 3~9 cm ( | > 9 cm ( | |||
|---|---|---|---|---|---|---|
| ≤ 3 vs. 3~9 | 3~9 vs. > 9 | ≤ 3 vs. > 9 | ||||
| Age, years | ||||||
| ≤ 50 | 212 (50.2%) | 534 (49.8%) | 139 (52.3%) | 0.928 | 0.519 | 0.662 |
| > 50 | 210 (49.8%) | 538 (50.2%) | 127 (47.7%) | |||
| Sex | ||||||
| Male | 346 (82.0%) | 928 (86.6%) | 223 (83.8%) | 0.0303 | 0.293 | 0.604 |
| Female | 76 (18.0%) | 144 (13.4%) | 43 (16.2%) | |||
| AFP, ng/mL | ||||||
| ≤ 20 | 183 (43.4%) | 471 (43.9%) | 72 (27.1%) | < 0.001 | < 0.001 | < 0.001 |
| 20–400 | 140 (33.2%) | 249 (23.2%) | 62 (23.3%) | |||
| ≥ 400 | 99 (23.5%) | 352 (32.8%) | 132 (49.6%) | |||
| HBV DNA, IU/ml | ||||||
| ≤ 1000 | 213 (50.5%) | 488 (45.5%) | 100 (37.6%) | 0.0951 | 0.0236 | 0.00126 |
| > 1000 | 209 (49.5%) | 584 (54.5%) | 166 (62.4%) | |||
| White blood cells, 109/L | ||||||
| < 4 | 131 (31.0%) | 236 (22.0%) | 41 (15.4%) | < 0.001 | 0.0218 | < 0.001 |
| ≥ 4 | 291 (69.0%) | 836 (78.0%) | 225 (84.6%) | |||
| Platelet count, 109/L | ||||||
| < 100 | 115 (27.3%) | 193 (18.0%) | 15 (5.6%) | < 0.001 | < 0.001 | < 0.001 |
| ≥ 100 | 307 (72.7%) | 879 (82.0%) | 251 (94.4%) | |||
| Albumin, g/L | ||||||
| < 35 | 10 (2.4%) | 29 (2.7%) | 14 (5.3%) | 0.852 | 0.0545 | 0.0717 |
| ≥ 35 | 412 (97.6%) | 1043 (97.3%) | 252 (94.7%) | |||
| Total bilirubin, μmol/L | ||||||
| ≤ 17.1 | 314 (74.4%) | 822 (76.7%) | 205 (77.1%) | 0.391 | 0.958 | 0.485 |
| > 17.1 | 108 (25.6%) | 250 (23.3%) | 61 (22.9%) | |||
| γ-Glutamyl transferase, IU/L | ||||||
| ≤ 64 | 300 (71.1%) | 663 (61.8%) | 62 (23.3%) | < 0.001 | < 0.001 | < 0.001 |
| > 64 | 122 (28.9%) | 409 (38.2%) | 204 (76.7%) | |||
| Alkaline phosphatase, IU/L | ||||||
| ≤ 129 | 410 (97.2%) | 998 (93.1%) | 181 (68.0%) | 0.00362 | < 0.001 | < 0.001 |
| > 129 | 12 (2.8%) | 74 (6.9%) | 85 (32.0%) | |||
| ALBI grade | ||||||
| ≤ − 2.63 | 321 (76.1%) | 795 (74.2%) | 154 (57.9%) | 0.486 | < 0.001 | < 0.001 |
| > 2.63 | 101 (23.9%) | 277 (25.8%) | 112 (42.1%) | |||
| Blood loss, mL | ||||||
| < 800 | 417 (98.8%) | 1024 (95.5%) | 209 (78.6%) | 0.00326 | < 0.001 | < 0.001 |
| ≥ 800 | 5 (1.2%) | 48 (4.5%) | 57 (21.4%) | |||
| Differentiation degree | ||||||
| I/II | 105 (24.9%) | 174 (16.2%) | 16 (6.0%) | <0.001 | <0.001 | <0.001 |
| III/IV | 317 (75.1%) | 898 (83.8%) | 250 (94.0%) | |||
| Microvascular invasion | ||||||
| Negative | 349 (82.7%) | 830 (77.4%) | 175 (65.8%) | 0.0292 | < 0.001 | < 0.001 |
| Positive | 73 (17.3%) | 242 (22.6%) | 91 (34.2%) | |||
| Tumor capsule | ||||||
| Incomplete/absent | 292 (69.2%) | 735 (68.6%) | 205 (77.1%) | 0.861 | 0.00827 | 0.0309 |
| Complete | 130 (30.8%) | 337 (31.4%) | 61 (22.9%) | |||
| Cirrhosis | ||||||
| Absent | 157 (37.2%) | 588 (54.9%) | 182 (68.4%) | < 0.001 | < 0.001 | < 0.001 |
| Present | 265 (62.8%) | 484 (45.1%) | 84 (31.6%) | |||
Fig. 2Overall survival of patients with solitary HBV-related HCC classified by tumor size into three new groups